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Mycobacterium tuberculosis (M.tb), the causative agent of tuberculosis (TB), is the 
current leading cause of death due to a single infectious organism. Although curable, 
the broad emergence of multi-, extensive-, extreme-, and total-drug resistant strains 
of M.tb has hindered eradication efforts of this pathogen. Furthermore, computational 
models predict a quarter of the world’s population is infected with M.tb in a latent state, 
effectively serving as the largest reservoir for any human pathogen with the ability to 
cause significant morbidity and mortality. The World Health Organization has prioritized 
new strategies for improved vaccination programs; however, the lack of understanding 
of mycobacterial immunity has made it difficult to develop new successful vaccines. 
Currently, Mycobacterium bovis bacillus Calmette–Guérin (BCG) is the only vaccine 
approved for use to prevent TB. BCG is highly efficacious at preventing meningeal and 
miliary TB, but is at best 60% effective against the development of pulmonary TB in 
adults and wanes as we age. In this review, we provide a detailed summary on the 
innate immune response of macrophages, dendritic cells, and neutrophils in response 
to BCG vaccination. Additionally, we discuss adaptive immune responses generated by 
BCG vaccination, emphasizing their specific contributions to mycobacterial immunity. 
The success of future vaccines against TB will directly depend on our understanding of 
mycobacterial immunity.
Keywords: tuberculosis, Mycobacterium tuberculosis, bacillus Calmette–Guérin vaccine, innate immunity, 
adaptive immunity
iNTRODUCTiON
Tuberculosis (TB) disease, defined by symptoms cause by infection with Mycobacterium tuberculosis 
(M.tb), is the leading cause of death from an infectious agent (1, 2). M.tb continues to spread due to 
the existence of a large reservoir of latently infected individuals who can reactivate at any time (3). 
Clinical options available to combat TB include chemotherapeutic agents and the preventative vaccine 
Mycobacterium bovis bacillus Calmette–Guérin (BCG). BCG is a live-attenuated strain of M. bovis 
originally developed for its potential to prevent TB and not M.tb infection, an important distinction. 
BCG vaccination is highly effective at preventing TB-meningitis and extra-pulmonary disseminated 
TB; however, its efficacy against pulmonary TB (PTB) in different human populations (children, 
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youth, adult, and elderly) varies. Some studies have shown 80% 
efficacy, whereas others have shown none (4, 5) [see Ref. (6) for 
a comprehensive list of BCG clinical trials]. Nonetheless, BCG is 
the most widely administered vaccine around the world for the 
prevention of M.tb-associated diseases (7).
The poor efficacy conveyed by BCG at preventing TB has been 
attributed to many factors, including human and mycobacterial 
genetics (8, 9), exposure to environmental mycobacteria (EM), 
coinfections with viruses and/or parasites, geographical location, 
and importantly, socioeconomic and nutritional factors (10–12). 
However, the fundamental question remains as to what consti-
tutes sterilizing immunity to TB, and why BCG fails to confer this 
state. BCG is primarily believed to mediate immunity through the 
development of antigen (Ag)-specific memory T  cells (13–15), 
which act quickly following a subsequent infection with M.tb. 
Indeed, this is the fundamental reason why BCG works against 
disseminated TB and TB meningitis (16, 17). However, why the 
same mechanism fails to prevent PTB remains poorly under-
stood. Despite this, researchers across the world have continu-
ously sought to modify and/or improve BCG. This began with 
genetic manipulations through deletions and insertions of genes 
from virulent mycobacteria that has today evolved into generat-
ing sophisticated multifunctional vaccine strains such as rBCG 
ΔureC:Hly+, the most promising vaccine candidate to replace 
BCG (5). Albeit conceptually and experimentally promising, the 
majority of these recombinant BCG vaccines fail at fully prevent-
ing the development of PTB (12).
It is still unclear why BCG fails to prevent primary infection, 
reactivation, and PTB, but it is widely accepted that generating 
long-term protective immunity is essential. Thus, developing 
a successful vaccine against M.tb infection or TB requires an 
understanding how immunity develops following BCG vaccina-
tion, and the roadblocks behind why protective immunity is not 
sustained. In this review, we explore the host innate and adaptive 
immune responses to BCG, and how these further influence the 
host response to M.tb infection and progression to TB. Finally, we 
discuss an important and commonly overlooked factor in BCG 
vaccine design, the influence of the human lung environment, 
and its consequences in directing the M.tb pathway of infection.
iNNATe iMMUNe ReSPONSeS  
TO BCG vACCiNATiON
Macrophages
Following BCG intradermal inoculation, resident epidermal 
macrophages interact with BCG via several pattern-recognition 
receptors (PRRs), including complement receptor 3 (CR3) (18) 
and toll-like receptors 2 and 4 (TLR2/4) (19). C-type lectin 
family receptors such as the mannose receptor (MR) and the 
macrophage inducible Ca2+-dependent lectin (MINCLE) recep-
tor are expressed on macrophages (20–22), but direct interaction 
between them and BCG, and its subsequent outcome, has not yet 
been described. Because the peripheral lipid portion of the cell 
wall is very similar between BCG and M.tb (23), it is predicted 
that their ability to infect tissue macrophages will be similar. 
However, BCG’s first contact occurs with resident epidermal 
macrophages, whereas M.tb contact, in the majority of cases, 
occurs with resident alveolar macrophages (AMs). Differences 
in the mechanisms of Ag recognition, Ag uptake, Ag processing, 
and Ag presentation between these two types of resident tissue 
macrophages remains unclear and may contribute to the reasons 
behind why BCG is not fully protective. Thus, resolving this dis-
crepancy will be important to identify if epidermal vaccination 
is sufficient to protect against lung disease. In fact, the effect of 
serum opsonization is often overlooked during BCG vaccina-
tion (24–26). This process is thought to be crucial in initiating 
immune responses to the BCG vaccine. As an example, the 
host opsonin factor H, a regulatory protein of the complement 
system that downregulates the alternative complement cascade, 
can bind to the BCG cell surface (27) and partially inhibit its 
uptake by epidermal macrophages. Macrophages infected by 
factor H opsonized BCG can secrete elevated amounts of pro-
inflammatory cytokines, potentially driving an acute response 
(high IL-6/TNF) (27). Thus, factor H opsonization of BCG could 
be detrimental to the primary goal of BCG vaccination (to gener-
ate a strong T cell memory response). This is probably because 
opsonized BCG gets killed too quickly, reducing the amount of 
time Ag is available for presentation, and thus negatively impact-
ing T cell proliferation and recruitment to the site of infection. 
Like factor H, there are other serum opsonins in the epidermal 
tissue and thus, further studies are necessary to assess their effects 
in the generation of immunity to BCG.
From the mycobacterial perspective, the TB field assumes 
that BCG cell wall components will interact in a similar fashion 
with macrophage receptors as M.tb cell wall components do (28). 
However, differences exist, such as in the case of the mannose-
capped lipoarabinomannan (ManLAM) of M.tb vs. BCG. The 
degree and pattern of mannose capping and fatty acid content 
in M.tb ManLAM vs. BCG ManLAM differs (28) and thus, it 
may dictate how this molecule is differentially recognized by 
macrophage receptors such as the MR, TLR2 (dimerized with 
TLR1 or TLR6), or TLR4, generating different immune responses 
that subsequently may affect Ag presentation. In fact, BCG 
macrophage stimulation via TLR2 or TLR4 drives differences in 
pro-inflammatory responses, T cell proliferation, and IFNγ secre-
tion in vitro and results in differences in bacterial burden in the 
lung in vivo (19). Indeed, prolonged Ag stimulation of TLR2 in 
macrophages downregulates the expression of major histocom-
patibility complex (MHC) class II and affects MHC I Ag cross 
processing, thus, reducing Ag presentation to T cells (29). It is still 
not clear to which degree suppression of MHC I and II via TLR2 
will negatively impact the protective immune response generated 
by BCG vaccination and/or against M.tb infection. In this regard, 
studies have shown the potential of introducing an adjuvant dur-
ing BCG vaccination targeting TLR-7/9 signaling, which restores 
and/or increases the expression of MHC II in macrophages, thus 
enhancing their ability to present Ag (30).
From the host perspective, differences in tissue-resident mac-
rophages (epidermal vs. lung) expressing different PRR types and 
levels (31, 32), as well as human polymorphisms in these recep-
tors, could influence immune responses to BCG and subsequently 
its effectiveness. Studies performed using BCG and M.tb indicate 
that the nature of their cell wall components engaging a specific 
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macrophage PRR determines the host immune response gener-
ated. For example in macrophages, engagement of ManLAM 
or higher-order phosphatidyl-myo-inositol mannosides (PIMs) 
to the MR drives an anti-inflammatory response; however, 
engagement of trehalose 6,6′-dimycolate (TDM) to MINCLE 
or engagement of lower-order PIMs to CR3 and/or TLRs results 
in pro-inflammation (28). Thus, the balance between pro- and 
anti-inflammatory lipids present on the BCG and M.tb cell wall 
is a factor to consider in the protective ability of BCG. Reducing 
pro-inflammation at the site of vaccination may be beneficial 
as macrophages will be exposed to the Ag for a longer period 
of time, and thus provide additional time for the generation of 
T  cell immunological memory. If we consider that epidermal 
macrophages and AMs in the lung have and/or use different PRRs 
for BCG recognition that leads toward site-distinct mechanisms 
of Ag presentation, then a safe delivery of BCG into the lungs 
could be a way to optimize BCG efficacy.
Differences in intracellular trafficking and Ag processing could 
also explain the failure of BCG to confer long-term immunity. 
In fact, BCG, as well as M.tb, can block phagosome maturation 
(33–35) by engaging specific receptors, i.e., the MR (36), and 
although MHC Ag presentation and activation of the adaptive 
immune system is unaffected, it may be less than optimal (37, 38). 
In this context, exogenous induction of phagosome–lysosome 
(P–L) fusion (39), autophagy (12), and/or increasing phagosome 
leakage of Ag across the phagosome membrane (40), could 
enhance the Ag-presentation process and thus, BCG efficacy.
An important step forward in the development of a new, effec-
tive TB vaccine, focused on optimizing Ag presentation, came 
from the development of the rBCG ΔureC∷hly vaccine (41). 
This vaccine, when administered percutaneously, has superior 
efficacy than BCG by further reducing the bacterial burden in the 
lung of M.tb-infected mice. Recent studies also indicate that vac-
cination with BCG ΔureC∷hly increases macrophage apoptotic 
vesicle formation, thereby inducing more robust CD4 and CD8 
T cell responses (42), as well as increasing the gene expression of 
“Absent In Melanoma 2.” This increases the autophagic pathway 
and inflammasome activation, which in turn improves control of 
M.tb infection (43). Thus, although P–L fusion is an important 
mechanism, modulation of apoptosis and autophagy can also 
offer novel avenues for vaccines against TB. Mechanistic studies 
such as these, focusing on the underlying factors behind enhanced 
immunity offer valuable insight into the requirements for efficient 
mycobacterial clearance.
Extending on the above findings, ex vivo M.tb-infected lung 
macrophages from BCG-vaccinated guinea pigs are shown to 
secrete larger amounts of IFNγ, TNF, and IL-12p40, highlighting 
their appropriate anti-mycobacterial response (44). Other sup-
porting ex vivo studies indicate that AMs from BCG-vaccinated 
guinea pigs challenged with M.tb express significantly less IL-10 
and more IL-12p40, compared to unvaccinated controls (45). 
This same study reported an elevated expression of MHC II on 
peritoneal macrophages from BCG-vaccinated guinea pigs (45). 
Thus, based on our current understanding of the requirements for 
mycobacterial immunity; immunity induced by the BCG vaccine 
results in responses to M.tb at the early phase of infection that 
directly impact macrophage function.
Altogether, there is a significantly large body of knowledge on 
the interactions between BCG and macrophages and how these 
responses can influence protective immune responses against 
M.tb. Receptor interaction between the macrophages and bac-
teria are critical in initiating the response, where interactions 
with different macrophage receptors can differentially modulate 
trafficking pathways and processing and presentation of Ag. 
However, additional studies determining the exact role of epider-
mal macrophages vs. AMs following BCG vaccination are needed 
before macrophage functions can be exploited to further improve 
vaccine development strategies. The innate immune response to 
BCG are highlighted in Figure 1.
Dendritic Cells (DCs)
Dendritic cells are classified as one of the most potent APCs (46) 
and classically described as the modulators of cross talk between 
innate and adaptive immunity (47). Phenotypic and functional 
differences exist between DCs and macrophages; however, the pri-
mary difference is that DCs, in contrast to macrophages, migrate 
from tissues via the lymphatic system and enter the draining lymph 
nodes, where they present Ags to naïve T cells (48) leading to the 
induction of effector T cell responses (49, 50). As DCs migrate, 
they mature by upregulating MHC II and CD80, CD86, CD40, 
and CD54 costimulatory molecules, all involved in the activation 
of adaptive immune cells (48, 51). Several phagocytic receptors 
on DCs recognize BCG, including CR3 (CD11b/CD18), CR4 
(CD11c/CD18), dendritic cell-specific ICAM-3 grabbing non-
integrin (DC-SIGN, CD209), and DEC-205 (CD205) (52–54). 
Of all these receptors, DC-SIGN is possibly one of the most 
important as neutralization of DC-SIGN with antibodies (Abs) 
inhibits the interaction of BCG with DCs by 80% (51). Signaling 
receptors such as TLR2 and TLR4 are also shown to be involved in 
DC activation and maturation by their interaction with BCG cell 
wall components (i.e., mAGP complex) (51, 55, 56).
Following BCG vaccination epidermal DCs initiate adap-
tive immune responses in  vivo by trafficking from the site of 
inoculation to draining lymph nodes where they present Ag to 
adaptive immune cells. In this context, migratory DCs display an 
EpCAMlowCD11bhigh phenotype and are capable of priming CD4+ 
T cells via interleukin-1 receptor and myeloid differentiation pri-
mary response gene 88 signaling pathways (57). However, most of 
our understanding of DCs and BCG immunology is from studies 
conducted in vitro. Stimulation of DCs with BCG in vitro induces 
homotypic aggregation, upregulation of surface Ag presenting 
molecules, downregulation of endocytic activity, and release of 
TNF (58), implying DCs initially respond to BCG. However, it is 
difficult to discern whether these responses are adequate for opti-
mal immunity. BCG can be engineered to enhance DC activation 
by the addition of M.tb genes encoding specific mycobacterial 
proteins into BCG (59), suggesting that DC responsiveness to 
BCG may not be optimal. Though immunity can be improved 
by augmenting DC activation, we still lack a fundamental 
understanding of the exact interactions or processes that result 
in optimal immunological protection. From the perspective of 
the host, mice lacking specific genes (e.g., IFNγ, IL-12, and TNF) 
have been valuable in deciphering some of the requirements for 
effective immunity to BCG and M.tb; however, they offer little 
FiGURe 1 | innate immune cell responses to bacillus Calmette–Guérin (BCG) vaccination. The initial immune response to BCG occurs at the site of 
inoculation (usually the dermal layer of the skin) where resident macrophages and dendritic cells (DCs) interact with the bacillus via different receptors expressed on 
their surface. Macrophages and DCs phagocytose the bacteria initiating the innate immune response through the secretion of immunomodulatory components such 
as cytokines and chemokines. Bacteria are degraded via intracellular killing mechanisms and their peptides are trafficked to the plasma membrane along with major 
histocompatibility complex (MHC) class I and II where they are presented to cells of the adaptive immune system. Neutrophils also enter the site of inoculation and 
participate in the response. Finally, DCs, loaded with bacteria, and expressing antigen on their surface, home to draining lymph nodes. Abbreviations: P–L, 
phagosome–lysosome; ROS, reactive oxygen species; RNS, reactive nitrogen species; CRs, complement receptors; TLR, toll-like receptors; GPCRs, G-protein-
coupled receptors; CLRs, C-type lectin receptors; MR, mannose receptor; MINCLE, macrophage inducible Ca2+-dependent lectin; NLRs, NOD-like receptors; 
FcγRs, Fcγ receptors; SRs, scavenger receptors; DLNs, draining lymph nodes; DC-SIGN, dendritic cell-specific intercellular adhesion molecule-3-grabbing 
non-integrin.
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insight as to the concentration and spatial organization required 
for their optimal efficacy. Transgenic mouse models allowing 
manipulation of specific gene products or conditional knockout 
mice allowing for spatial regulation could be useful in elucidating 
the necessary elements for optimal BCG efficacy in terms of space 
and time.
Stimulation of human DCs with BCG can increase surface 
expression of MHC-II, CD40, CD44, CD54, CD80, and CD86, 
all markers involved in DC activation, maturation, migration, 
and Ag presentation to T cells (60). DCs infected with BCG also 
secrete TNF, IL-1β, IL-6, IL-4, and IL-10, but not IL-12 (61). 
Strikingly, IL-4 is secreted at large concentrations indicating that 
its presence could shift immunity from a Th1 polarized response 
toward a Th2 response, potentially affecting BCG efficacy (62). 
However, recent studies disproved this hypothesis by showing that 
BCG-infected DCs cocultured with T cells are capable of induc-
ing T cell proliferation and IFNγ secretion in vitro, the defined 
Th1 cytokine critical for the control of M.tb (63). However, IFNγ 
is shown to correlate poorly with protection against mycobacteria 
infection and disease (64, 65). Thus, more refined markers such 
as abundance of memory lymphocytes in the lung and multifunc-
tional T cell diversity have arisen as better indicators of functional 
immunity (discussed below) (17, 66). Furthermore, reports 
indicate that M.tb hinders the efficiency and effectiveness of Ag 
presentation by macrophages and DCs (67, 68), whereas BCG is 
much more efficient at stimulating CD4+ T lymphocytes. Thus, 
although BCG may effectively stimulate the process of Ag pres-
entation, the capacity of BCG-infected DCs to present Ag may be 
at a saturation point, and any further stimulation of the adaptive 
immune system may not be achievable (69). In this context, 
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attempts such as BCG-expressing Fms-like tyrosine kinase 3 
ligand [Flt3L, a hematopoietic growth factor that stimulates DC 
proliferation, and whose deletion reduces T cell responses by 50% 
(70)] did not show further enhancement of BCG efficacy against 
M.tb challenge. This finding is independent of early expansion of 
DCs and increased stimulation of BCG-reactive IFNγ-secreting 
T cells (71). As BCG may be less efficient in inducing DC matu-
ration than M.tb, understanding the differences between them 
could lead to greater approaches in improving the interaction 
between BCG and DCs and thus, host immunity (72).
Several groups have exploited DC maturation to improve BCG 
immunity, with studies centered in modulating TNF and IL-10 
dominating the field. TNF neutralization inhibits DC maturation 
post-BCG inoculation suggesting an important role for TNF 
in immunity generated by BCG (60). As a result, an adequate 
concentration of TNF is required for optimal DC Ag-presenting 
efficacy. BCG-infected DCs also secrete large quantities of IL-10, 
but not IL-12 (61). IL-12 is, however, highly expressed in IL-10−/− 
mice following inoculation with BCG indicating the existence 
of an important balance between IL-10 and IL-12, which could 
activate/accelerate maturation of DCs (35) and serve as a potential 
host-directed therapy. These findings may explain why DCs from 
IL-10−/− mice are more efficient at activating T cells in the draining 
lymph nodes (DLNs) (73). Thus, IL-10 may not only downregulate 
the migration of infected DCs to the DLN but also regulate IL-12 
production and subsequent DC capacity to mature, diminishing 
T cell activation and proliferation, repressing the adaptive immune 
response generated by BCG (73, 74), and possibly affecting the 
development of immunological memory. Hence, downregulation 
of IL-10 and upregulation of IL-12 could to be important for 
generating an optimal immune response to BCG.
Apart from being powerful mediators of the immune response 
to BCG by initiating innate responses, DCs also translate informa-
tion to the adaptive branch of the immune system and initiate the 
first steps that subsequently give rise to immunological memory. 
With this in mind, it is logical to explore mechanisms that can 
enhance DC–BCG interactions with intentions of amplifying 
BCG efficacy. Although the DC–BCG interaction appears to 
be highly efficient, it remains unclear why they fail in the lung. 
One could speculate that too much focus has been placed on 
DC responses to BCG in vitro and thus, it has misconstrued our 
notion of DC responses.
Neutrophils
Circulating human neutrophils comprise approximate 60% of the 
blood cells, have a short half-life of 6–10 h, and are one of the first 
cells to respond to foreign molecules (75). Neutrophils secrete 
large amounts of chemokines and cytokines, priming long-lived 
phagocytes (76). Interaction of neutrophils with BCG increases 
their expression of adhesion markers CD11b and CD18, FcγRs 
II and III, and stimulates their upregulation of cytokines (e.g., 
IL-1α, IL-1β, and TGFβ) and chemokines (e.g., IL-8, CCL2, and 
CCL3) (77). How changes in neutrophil phenotype upon contact 
with BCG can influence the generation of protective immunity 
against M.tb is still unclear.
Neutrophils are capable of shuttling live BCG via the lym-
phatic system into DLNs and into the vicinity of DCs and T cells 
(78). The cross talk between BCG-infected neutrophils and DCs 
in this location delivers maturation signals to immature DCs and 
also assists DCs in their presentation of BCG Ags to prime CD4+ 
and CD8+ T  cells (78–80). The delay in apoptosis observed in 
BCG-infected neutrophils supports the concept that BCG may 
use them as a vehicle to disseminate from the site of inoculation 
to DLNs (81). However, whether the host benefits from the neu-
trophil–BCG interaction remains unanswered. Additionally, the 
longer BCG remains within neutrophils increases the probability 
the bacteria will be killed by neutrophil intracellular mechanisms, 
possibly enhancing pathways involved in immune activation via 
Ag presentation (82). Studies conducted in the C3HeB/FeJ mice, 
which develop necrotic and hypoxic tubercle granulomas, found 
that BCG vaccination in these mice was associated with long-
lasting immunity and reduced bacterial burden. The association 
was attributed to a reduction in the numbers of neutrophils (83). 
Thus, neutrophils may behave as a double-edged sword; on one 
hand, they seem to facilitate Ag presentation by shuttling live 
bacilli to the vicinity of DCs, but on the other hand, they may 
be responsible for preventing the development of long-lasting 
immunity. The balance between BCG’s intracellular survival 
and/or digestion, processing, and presentation by the neutrophil 
may impact DC maturation, the subsequent adaptive immune 
response (limiting the clonal expansion of Ag-specific effector 
lymphocytes), and the long-term establishment of a state of 
protective immunity.
Conversely, neutrophils can also direct activation of T cells 
in lymph nodes, and thus participate in the generation of adap-
tive immune responses (80, 84). A recent study indicates that 
neutrophils expressing CCR7 migrate to the lymph nodes in 
response to CCR7 ligands, CCL19 and CCL21. This migration 
seems enhanced during in vivo injection of complete Freund’s 
adjuvant (containing inactivated M.tb cell wall) in wild-type 
mice, but not CCR7−/− mice (85). To further illustrate a role for 
neutrophils, studies using mice inoculated with BCG via the 
intranasal route show neutrophils entering the lungs in two 
waves. The first wave arrives between 1 and 3 days post-inocu-
lation and could kill M.tb. The second wave of neutrophils enters 
the lung 3  weeks post-inoculation together with IFNγ- and 
IL-17A-producing T  cells. This second wave of neutrophils is 
not associated with the ability to kill M.tb, and their movement 
into the lungs is dependent on the expression of IL-17RA (86). 
Subsequent studies show that M.tb-infected neutrophils are a 
prominent population in the lungs early during infection (87), 
and that M.tb-infected neutrophils promote adaptive immune 
responses to M.tb infection. Recent studies using BCG also 
demonstrate that neutrophils regulate inflammation via the 
secretion of IL-10, impairing the control of M.tb growth dur-
ing chronic infection (88); thus, further establishing the dual 
role for neutrophils during infection, being active in not only 
controlling M.tb infection but also regulating the inflammatory 
response generated during infection. Since neutrophils enter 
tissues much sooner relative to other host cells, they could be 
a critical mediator in clearance or persistence of mycobacteria. 
However, how the regulatory functions of neutrophils influence 
adaptive memory responses generated by BCG vaccination 
remains unanswered.
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Altogether, neutrophils can have a wide range of effects in 
the context of BCG vaccination. On one hand, they may help 
facilitate adaptive immune responses by aiding in Ag presentation 
and shuttling live bacteria into the vicinity of professional APCs, 
but on the other hand, their presence and propensity to induce 
strong inflammatory responses may be detrimental to the tissue 
in which they reside, propagating the disease, and potentially 
inhibiting the development of long-lasting immunity. Indeed, it 
remains unclear whether neutrophil shuttling of BCG is benefi-
cial or detrimental as they may ultimately be used as a vehicle 
from which to disseminate to other organs. Further studies as 
to the role of neutrophils and mechanism in which they may be 
involved post-BCG vaccination could shed some light on the 
complex behavior of neutrophils.
ADAPTive iMMUNe ReSPONSeS  
TO BCG vACCiNATiON
T Lymphocytes
T  cell responses arise in parallel through engagement of the 
T receptor with foreign Ag presented by Ag-presenting cells (89). 
With few exceptions, all vaccines stimulate the proliferation of 
CD4+ helper T cells (Th) and CD8+ cytotoxic T cells (Tc) (14). In 
the context of BCG immunity, helper T cells primarily differenti-
ate into two distinct classes of effector cells during an immune 
response to vaccination: Th1  cells identified by the production 
of IFNγ, and Th17 cells identified by the production of IL-17A, 
though IL-4 producing Th2 cells can also be generated (90). Other 
cell subsets such as T regulatory cells (Treg) and CD1-restricted 
T  cells also arise following BCG vaccination, albeit to a lesser 
extent. BCG also induces cytotoxic T cells, whose main function 
is to lyse infected cells through osmotic disruption (91). It is clear 
that both CD4+, and to a lesser extent CD8+, T cells are critical 
for protection against M.tb infection; experimentally highlighted 
using mouse knockout models (92–95) supporting a dominant 
role for T  cells as the main effector cells following immuniza-
tion with BCG. The adaptive immune responses to BCG are 
highlighted in Figure 2.
CD4+ and CD8+ T Cells
Mouse models have confirmed that α/β T cell receptor expressed 
by CD4+ and CD8+ T cells and MHC I and II are necessary for con-
trol of mycobacterial infections (96, 97), highlighting a dominant 
T cell response to BCG. Adoptive transfer studies provide the best 
evidence that protective T cell mediate immunity is generated by 
BCG. The transfer of CD4+ or CD8+ T cells from BCG-vaccinated 
mice into rag1−/− mice, an in vivo model deficient for both B and 
T  cells, show that CD4+ T  cells are necessary to reduce bacte-
rial burden in the lung and spleen, while CD8+ T cells control 
bacterial burden only in the spleen. These results implicate CD4+ 
T cells as the main effector cell generated by BCG in the lung, 
and also highlight the importance of CD8+ T cells in preventing 
dissemination (98–101), potentially making them the main effec-
tor cell responsible for preventing miliary TB and TB meningitis. 
However, despite the fact that CD4+ T cells reduce BCG burden 
in the lung, BCG is not eliminated, indicating that their effector 
functions in the lung may be limited. BCG vaccination followed 
by M.tb challenge confirms that in the absence of CD4+ T cells, 
CD8+-specific T cells are able to reduce M.tb bacterial burden in 
the lung at later time-points postinfection, supporting the impor-
tance of CD8+ T cells during the later phases of the disease (98, 
102). These data demonstrate that BCG can stimulate protective 
CD4+ and CD8+ T cells and also suggest that CD4+ T cells are not 
as efficient as their CD8+ T cell counterparts when it comes to 
clearing a mycobacterial infection in a tissue-specific context, or 
perhaps the unique environment of the lung makes it difficult for 
CD4+ T cells to assert their functions. The answer could also lie in 
the pathogen itself as M.tb possesses many virulence factors that 
are not present in BCG that may be used to inhibit CD4+, but not 
CD8+, T cell responses.
The effector function of CD8+ T cells following BCG vaccina-
tion has been characterized to a lesser extent than CD4+ T cells 
(65). Whereas CD4+ T cells mediate their function by primarily 
activating cells of the innate immune system through engage-
ment of costimulatory molecules on innate cells, CD8+ T  cell 
responses, though similar, are not as capable of this function 
(98). Although there is a widely held view that BCG induces 
poor CD8+ T cell responses in vivo, human studies line up with 
in  vitro studies showing that BCG vaccination induces robust 
Ag-specific CD8+ T  cell responses characterized by increased 
IFNγ production, degranulation, proliferation, and elevated lev-
els of cytotoxic proteins (103). However, the mechanism by which 
CD8+ T cells contribute to the efficacy of BCG, such as cytotoxic 
function, stimulation of other cells via cytokines, chemokines, 
or microbicidal molecules, remains elusive. One mechanism 
that has received little attention is the ability of CD8+ T cells to 
induce apoptosis of cells via the FasL–Fas pathways, whereby 
CD8+ T cells lyse target cells expressing Fas (104). By inducing 
apoptosis of infected cells, other healthy innate immune cells can 
phagocytose the produced apoptotic bodies and further stimulate 
cells of the adaptive immune system. Thus, another explanation 
for the superior ability of CD8+ T cell to control dissemination of 
M.tb could lie in their ability to induce the FasL–Fas pathway in 
the spleen or liver, whereas apoptosis of cells in the lung is highly 
restricted to prevent excessive tissue damage that can lead to pul-
monary failure. In this context, one could envision an engineered 
BCG vaccine that induces apoptosis of infected cells allowing for 
a more efficacious vaccine against M.tb infection.
One argument frequently linked to the poor efficacy of BCG is 
the age at which BCG is administered, usually at the time of birth. 
As neonates are exposed to various Ags when born, it is believed 
that T cells are biased toward a Th2 response to prevent excessive 
inflammation. As a Th2 response can be detrimental to mycobac-
terial immunity, BCG vaccination of neonates may not fulfill its 
potential (105–109). However, studies in human newborns and 
infants reported a Th1 biased response following BCG immu-
nization similar to immunized adults (110, 111). These studies 
observed a high number of IFNγ+CD4+ T cells (112, 113), and 
also a significant population of CD4+ T cells negative for IFNγ 
but instead positive for TNF and IL-2 (114) indicating that BCG 
generates diverse and adequate immune responses required to 
contain M.tb in infants. Thus, it seems that poor efficacy of BCG 
against M.tb may not be due to the failure of generating Th1 cellular 
FiGURe 2 | Adaptive immune cell responses to bacillus Calmette–Guérin (BCG) vaccination. Upon entering the lymph nodes, dendritic cells stimulate 
CD4+, CD8+, CD1+-restricted T cells, TFH, T regulatory cells, and B cells. CD4+ and CD8+ T cells migrate out of the lymph nodes toward the site of inoculation and 
provide the necessary stimulation to innate cells. CD4+ T cells differentiate into Th1, Th17, or Th2 cells depending on the stimuli present in their microenvironment and 
aid in the activation of macrophages, whereas CD8+ T cells mediate their functions by lysing infected cells or by secreting cytokines. B cells differentiate into 
antibody producing plasma cells or memory B cells. Throughout the process, memory cells arise from those that responded to the infection and populate peripheral 
organs, such as the lung. Together, the cells of the adaptive immune systems orchestrate the immune response in an attempt to establish mycobacteria immunity. 
Abbreviations: EM, environmental mycobacteria.
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immunity at the time of vaccination. On the other hand, it is 
reported that cytokine and chemokine production differs in chil-
dren vaccinated with BCG in Malawi and the United Kingdom 
(UK) (115, 116). These studies pointed out that Malawian infants 
produce more cytokines associated with Th17 and Th2 immunity 
compared to infants from the UK. An explanation for this could 
be the environment surrounding the BCG-vaccinated infants 
[e.g., parasitic coinfections that dampen protective immune 
responses (117), or EM (118)]. Indeed, oral tolerance to EM is 
a detrimental factor following intradermal BCG vaccination, an 
effect that could be overcome by vaccinating via the pulmonary 
route due to lack of tolerance to EM in the lung (119). However, 
virulent lipids on the mycobacterial cell wall (including M.tb 
and M. bovis BCG), particularly TDM, have prevented the use 
of pulmonary vaccination. TDM is a highly toxic glycolipid that 
induces the formation of granulomas and a significant contribu tor 
of immunopathological damage to the lung during mycobacterial 
infections (120). Thus, another approach would be to focus on the 
bacteria itself and the biochemical properties associated with its 
cell wall that enable it to subvert host immunity. Despite whether 
BCG is efficacious or not at generating a strong Th1 response at 
birth, immunity appears to wane as we age. Thus, the problem of 
sustaining anti-mycobacterial immunity arises. Careful analysis 
of the mechanisms that protect against M.tb in the first decades of 
life post-BCG immunization could yield valuable clues to extend 
the duration of immunity generated by this vaccine.
CD4+ Th17 T Cells
Th17 responses in the lung are associated with both increased pro-
tection against M.tb infection (121) and exacerbated pathology 
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(122). On one hand, repeated BCG vaccination exacerbates the 
influx of granulocytes/neutrophils into the lung in an IL-17A-
dependent manner leading to extensive immunopathology. On 
the other hand, IL-17A is required to sustain IFNγ responses by 
CD4+ T cells in the lung. In mice, BCG stimulates Th17 responses 
within the lung (123). Thus, the presence of IL-17A in the lung 
may be important in generating an effective immune response that 
benefits the host (bacterial control with limited inflammation) 
or an immune response that ultimately damages the host (initial 
bacterial control with too much inflammation that subsequently 
leads to uncontrolled bacterial growth). Studies point out the role 
of IL-17A in the immune response to M.tb (124), particularly 
during initial granuloma formation (125). Interestingly, high 
concentrations of IL-17A that limit lung pathology are corre-
lated to the presence of IL-10 (126). Although the relationship 
between IL-17A and IL-10 remains unclear, IL-10 appears hav-
ing an immunosuppressive role during the generation of BCG 
immunity (127), and like IL-17A (121), IL-10 plays an important 
role during the initial stages of M.tb infection in vivo (128). The 
role of Th17 cellular responses in the context of BCG immunity 
remains uncertain, as indicated by recent studies demonstrating 
that the M.tb glycoprotein Rv1860/mpt32 (Apa or 45 kDa, present 
also in BCG) can downregulate Th17 and Th1 immune responses, 
abrogating BCG immunity against M.tb (129). However, this 
is in direct contrast to other studies where the same protein is 
shown to stimulate IFNγ-secreting CD4+ and CD8+ T cells (130) 
preventing the waning of BCG immunity, thus decreasing M.tb 
burden post-challenge (131). An explanation for these opposing 
results could lie in how the Rv1860 protein is utilized; in the 
former study, a recombinant BCG expressing Rv1860 was used 
to vaccinate mice, whereas in the latter, Rv1860 was administered 
as a booster in BCG-primed mice. This example highlights the 
complexity of the immune system and how certain mycobacterial 
proteins may be detrimental or beneficial in the development of 
the initial immune response depending on time and place and 
may or may not be required for optimal long-term immunity. In 
further support of Th17 cells as critical mediators of immunity to 
BCG, it has been shown that accelerated Th1 memory responses 
in the lung of BCG-vaccinated mice are dependent on IL-17A 
and IL-23 derived from Ag-specific memory Th17 cells, and that 
these lung-resident memory Th17 cells quickly respond to M.tb 
infection (121). With this in mind, BCG vaccination in unison 
with host-directed therapies that augment Th17 responses in the 
lung could be a powerful strategy to increase the efficacy of BCG.
T Regulatory Cells
T regulatory cells have also emerged as important players fol-
lowing immunization with BCG. BCG vaccination trials have 
partially associated BCG efficacy with the geographical location 
where the trial is conducted. Low BCG protective efficacy is 
reported in regions of the world closer to the equator, where EM 
are common. Thus, BCG protective efficacy could be affected 
by prior host Treg cell development due to pre-exposure to EM 
(119). The importance of CD4+ Treg cells mainly relies on studies 
showing that their depletion decreases M.tb burden in BCG-
vaccinated mice (132). Similarly, BCG boosted with an Ag85 
M.tb-protein construct (Ag85-Mpt64190–198-Mtb8.4) significantly 
decreases the number of Treg cells and that their depletion corre-
lates with reduced bacterial burden in the lung of M.tb-infected 
mice (133). Furthermore, human studies in BCG-vaccinated 
adults, who responded with strong immunization-induced local 
skin inflammation, showed significantly increased levels of 
protective multifunctional CD4+ T cells (134). However, BCG-
vaccinated adults who developed mild local skin inflammation 
showed increased levels of regulatory-like CD8+ T cells (134). 
Thus, factors that influence vaccination-induced inflammation 
could affect the development of Treg cells, for example, due to 
genetic polymorphisms within populations or their exposure 
to certain environments. If certain populations have a predis-
position toward generating a strong Treg cell response, BCG 
vaccination may be less effective. Thus, understanding genetic 
differences between human populations, and in particular 
changes brought forth by their living environment, could yield 
useful clues as to why BCG fails to protect them against M.tb. 
In fact, an important factor to consider in this matter is that 
many studies on EM are carried out by first exposing animals to 
EM followed by BCG vaccination. Since BCG is given at birth, 
exposure to EM likely occurs after BCG administration. Hence, 
the above studies highlight that a vaccine booster (BCG or other) 
after exposure to EM may not aid in the development of any 
further immunity where Treg cells may play a role (135). Overall, 
Treg cells may be detrimental to BCG vaccine efficacy against TB 
if there are pre-exposures to EM, thus blocking their function 
during BCG vaccination could be critical in inducing optimal 
immunity to M.tb.
CD1-Restricted T Cells
As the mycobacterial cell wall is primarily 80% lipid (136), studies 
have also focused on elucidating the role of CD1-restricted Ag 
presentation during BCG vaccination (137). BCG immunized 
humans harbor a pool of CD1-restricted CD8+ T cells recogniz-
ing BCG-infected DCs (138). Studies in guinea pigs support this 
finding, showing that BCG vaccination induces humoral and 
CD1-restricted cytotoxic T  cell-mediated immune responses 
stimulated by mycobacterial lipids and lipoglycans (139). Perhaps 
these lipid-restricted CD8+, T cells mediate immune responses 
in peripheral organs such as the spleen and liver and are thus 
responsible for maintaining the chronic stage of the disease and/
or help establish latent infection. This CD1-restricted CD8+ T cell 
population could also be the mediator that prevents disseminated 
TB and TB meningitis. Unfortunately, the absence of group one 
CD1 molecules (CD1a, CD1b, and CD1c) in mice (140) has made 
it difficult to elucidate the exact role of the CD1-restricted CD8+ 
T cell population to BCG immunity and during M.tb infection.
Mucosal-Associated Invariant T (MALT) Cells
Innate-like MR1 (non-classical MHC-1b)-restricted CD8+ 
T cells, called MAIT cells, are also defined as important players 
in mycobacterial immunity by potentially acting as early sentinels 
to M.tb infection (141). Despite individuals with TB having low 
levels of circulating MAIT cells (142), these cells respond to BCG 
stimulation by producing higher levels of TNF and IFNγ (143). 
Thus, further studies are necessary to clarify the positive or nega-
tive impact of MAIT cells in the context of BCG immunity.
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Multifunctional T Cells
Evidence for other correlates of protective immunity rose with 
the discovery of multifunctional CD4+ T cells, which simultane-
ously produce multiple cytokines (usually TNF, IFNγ, IL-17A, 
and IL-2). The contribution of these cells to mycobacterial 
immunity have been thoroughly discussed elsewhere (144), 
but it is important to stress that multifunctional T cells do not 
always correlate with protective immunity (145), and their 
importance should be carefully evaluated. As an example, the 
MVA85A vaccine (modified vaccinia virus Ankara made to 
express Ag 85A from M.tb) is developed as an intranasal booster 
to BCG. BCG-vaccinated, MVA85A-boosted individuals have 
significant increases in multifunctional T  cells compared to 
BCG alone leading many to speculate that MVA85A would 
enhance the efficacy of BCG. However, further studies revealed 
that with or without the MVA85A booster, BCG-vaccinated 
individuals are equally susceptible to TB (145). Thus, multi-
functional T cells may be a part of the puzzle (146), but may not 
contribute so significantly to protective immunity against TB as 
initially thought.
Overall, these findings reveal the complex nature of vaccinat-
ing with a live multifaceted organism such as BCG, where it is 
difficult to target only one branch of the immune system and 
generate effective, long-lasting immunity that prevents M.tb 
infection and the development of TB. Although the necessity of 
CD4+ T cells is without question, perhaps the reason why immu-
nity fails in the lung is not due to poor CD4+ T cell responses 
per  se, but rather due to inhibitory mechanisms in the lung 
preventing immunopathology. As highlighted above, the major 
role for CD8+ T cells appears to be in maintaining the chronic 
phase of the disease and seems to be particularly important in 
peripheral organs. Thus, it may not necessarily be that BCG is an 
inneffective vaccine; it may be that the lung inhibits BCG from 
living up to its full potential. Defining the contributions, whether 
good or bad, of other adaptive immune cell subsets (Th2, Th17, 
Treg, CD1-restricted, multifunctional, etc.) is also important. 
Additionally, variability in human genetics and the geographical 
environment in which we reside may have consequences on our 
ability to mount immune responses to vaccines and should be 
considered when designing future trials to test new TB vaccines. 
The problem of understanding the adaptive immune response 
to M.tb is further complicated by animal models that do not 
exactly recapitulate TB in humans. M.tb has evolved to infect 
humans and thus, humans may be the only species possessing 
the key to elucidating the mechanisms responsible for clearance 
of mycobacteria.
B Lymphocytes
The generation of long-lasting immunity to most pathogens by 
current effective vaccines relies on long-lived humoral immune 
responses that mediate protection via Abs (14). The BCG vac-
cine is a strong inducer of humoral immunity; however, due to 
the intracellular nature of M.tb infection, the potential of Abs as 
significant contributors to protective immunity has been largely 
disregarded. However, new evidence has emerged identifying a 
potential role for Abs and B cells in the immune response gener-
ated by BCG vaccination (147, 148). Researchers have begun to 
unravel a more significant role for B cells than solely Ab produc-
tion in the context of mycobacterial infections (149, 150).
Ab Responses to BCG Vaccination
Although M.tb intracellular modus vivendi within host cells limits 
Ab function, rapid and effective Ab opsonization of M.tb prior to 
entry into phagocytes could be a mechanism resulting in clear-
ance by innate immunity. Studies have demonstrated that BCG 
vaccination induces long-lived mycobacteria-specific memory 
B cells in healthy individuals (151), but details about their role 
in establishing immunity to BCG remain unclear. Early studies 
looking at Abs following BCG vaccination show agglutination 
in serum from BCG-vaccinated patients when incubated with 
M.tb Ags (152). Following this discovery, the humoral immune 
response following BCG vaccination (153–156) is associated with 
high levels of Ab production (157, 158), specifically linked to a 
progressive increase in the levels of immunoglobulin (Ig) M and 
IgG Ab isotypes IgG1, IgG2, and IgG3, the latter being induced 
by Th1 cytokines (159, 160). Overall, these studies identified 
robust humoral immune responses following BCG immuniza-
tion, indicating that the BCG vaccine itself can reliably induce 
Ab responses. In the context of M.tb infection, low IgM and IgG 
levels are also partially linked to TB susceptibility (161, 162); an 
indication that perhaps a rapid humoral immune response in the 
lung may prevent M.tb infections by mitigating M.tb entry via 
portals that favor its establishment [i.e., M.tb ManLAM/host the 
MR (36)].
IgA is the most abundant Ab in the lung mucosa compris-
ing approximately 30% of the total (163). Studies of IgA during 
BCG vaccination showed that IgA deficient (IgA−/−) mice have 
increased susceptibility to BCG infection and reduced production 
of both IFNγ and TNF in their lungs (164). IgA is shown to have 
a dual role, increasing phagocytosis of microbes and synergize 
with IgG to enhance cell-mediated cytotoxicity by effector T cells 
and also blocking IgG pathogen opsonization (163), potentially 
preventing interactions with Fcγ receptors. Thus, proper levels 
of IgA in the lung mucosa may determine the initial establish-
ment of infection with M.tb. This finding is supported by other 
studies using polymeric IgR knockout (pIgR−/−) mice, where pIgR 
mediates active transport of dimeric IgA (165). As in the case 
of IgA−/− during BCG infection, pIgR−/− mice are also more sus-
ceptible to M.tb within the first 3 weeks of infection, mainly due 
to an increased influx of neutrophils to the site of the infection. 
Thus, the development of a new recombinant BCG strain capable 
of inducing the production of IgA-committed memory B  cells 
may provide a good strategy to consider for the development of a 
mucosal vaccine. Given that we do not yet know how long M.tb 
remains in an acellular state following initial encounter with a 
host, Abs could mediate the very first interaction between the 
host cells and M.tb. As an example, opsonization of M.tb with Abs 
and subsequent entry via Fcγ receptors could result in increased 
bacterial killing compared to entry of M.tb via the MR (36). Given 
the large number of individuals exposed to M.tb, it is surprising 
that few develop the disease and instead remain healthy (PPD 
and/or QTF negative). BCG could be engineered to increase the 
presence of protective neutralizing/opsonizing Abs in the lung 
mucosa, so when M.tb is encountered it is quickly neutralized. 
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Further research on Abs in the context of M.tb vaccine design 
could answer some of these pressing questions.
Cell-Mediated Responses to BCG Vaccination
The specific role of B cells has also been studied in the context of 
BCG vaccination (149) to a certain extent. In this regard, studies 
using BCG-vaccinated μMT mice [lacking one of the IgM μ-chain 
transmembrane regions and thus cannot produce mature B cells 
or secrete Abs of any isotype (166)] showed that these can retain 
the typical 1.0-log10 reduction in bacterial burden in their lungs 
following M.tb infection (167). This finding directly questions the 
role of B cells in the control of M.tb infection and suggests that 
B  cells may not play a measurable protective role during BCG 
vaccination in mice. However, these studies do not completely 
rule out that BCG-induced Ab responses or B-cell-dependent 
costimulation could be targeted to prevent M.tb infection in the 
first place. In fact, a non-Ab-mediated role of B cells has recently 
emerged with the study of Follicular B helper T cells (THF). TFH 
are Ag-experienced CD4+ T cells found within secondary lymph 
node organs (e.g., spleen, lymph nodes) in the vicinity of B cell 
follicles (168). These cells are important in mediating the selection 
and survival of B cells and stimulate their transition into plasma 
cells and memory B cells (169). Recently, TFH cells have emerged 
as important mediators in the development of BCG immunity. 
While studying the BCG ΔureC∷hly vaccine, it was discovered 
that the superior efficacy behind this vaccine correlates with 
higher levels of central memory T cells and TFH cells (170, 171). 
Though promising, further research will reveal the importance of 
TFH in the context of mycobacterial immunity.
There are still many unknowns regarding B  cell immunity 
against M.tb, in particular in the context of BCG immunization. 
The role of Abs, though previously largely dismissed, could be 
targeted to prevent infection with M.tb. For example, by gen-
erating a long-lasting pool of M.tb-specific Abs within the lung 
mucosa, M.tb could be neutralized before it has the opportunity 
to encounter alveolar compartmental cells where it is shielded 
from opsonins. The cross talk between B and T cells could also 
play an important role in host defense against M.tb, including 
priming effective memory T  cell responses. An important 
Ab-independent function for B cells is also plausible, as reported 
for other intracellular pathogens (172). Hence, whether B cells 
can be targeted by new vaccines to contribute via Ab-mediated 
processes or by interaction with other cells of the adaptive immune 
system to prevent M.tb infection requires further investigation.
ADJUvANTS AND BCG
Because we lack correlates of immunity to M.tb, research and 
development of new adjuvants that may enhance BCG immunity 
has been challenging [for details on TB vaccine adjuvants, see 
Ref. (173, 174)]. Whereas older adjuvant formulations relied 
on the use of cell wall extracts in liposomes or oil droplets 
(175, 176), modern adjuvants for TB vaccines target stimulation 
of PRRs including TLRs and MINCLE (174, 177). Adjuvants 
include cationic lipids, micro-/nanoparticles, toxin derivatives, 
CpG-containing DNA-based molecules, mycobacterial proteins 
conjugates, cytokines, and antimicrobial proteins (174). There 
are multiple studies examining adjuvant/adjunct molecules in 
combination with BCG to modulate innate responses and modify 
adaptive function boosting BCG efficacy (174, 178). In particular, 
lactoferrin, a host-secreted mediator that bridges innate and 
adaptive immune function in mammals (179), can act as an 
adjuvant with BCG protecting the lung alveolar integrity upon 
challenge with M.tb (180, 181). Adjuvants also make subunit 
vaccines more effective in boosting BCG (174), as a promising 
example is the IC31 adjuvanted H56 (182). This multistage vac-
cine is capable of boosting BCG efficacy delaying and reducing 
clinical disease in cynomolgus macaques challenged with M.tb 
and can prevent reactivation of latent infection (182). In general, 
adjuvants mediate their activities by (i) generating Ag depots, (ii) 
stabilizing Ag and protecting it from degradation, (iii) target-
ing Ag to specific cells, (iv) delaying or accelerating Ag uptake, 
(v) enhancing Ag presentation mechanisms, and (vi) directing 
stimulation of CD4+ and/or CD8+ T  cells (174). However, the 
majority of studies designed to test adjuvant efficacy have tar-
geted IFNγ responses, and as newer evidences suggest, IFNγ is 
an unsuitable marker of protection against M.tb. Although we 
continue to garner valuable knowledge on the mechanisms of 
action of adjuvants and how they can be improved, we must refine 
immunological correlates of protection if we are to use adjuvants 
to improve TB vaccine efficacy.
THe QUeST FOR A BeTTeR ANiMAL 
MODeL TO evALUATe TB vACCiNeS
The lack of a validated animal model for TB vaccine development 
is a current critical issue in the field. There are several animal 
models routinely being used for TB vaccinology studies: mice, 
guinea pigs, and non-human primates (NHPs) are the most com-
mon ones.
Infection with M.tb in humans typically results in one of three 
outcomes. First, on rare occasions, M.tb can be quickly contained 
and the infection cleared with or without the assistance of the 
adaptive immune system. Although there is little evidence for 
this scenario, some individuals remain PPD negative despite 
exposure to M.tb (183). Second, in 90–95% of cases, the infec-
tion progresses into latency. During latent tuberculosis infection 
(LTBI), adaptive immune cells surround infected macrophages 
and form an enclosed structure called a granuloma. Individuals 
with LTBI can live their entire life without any symptoms of the 
disease. However, they have a 10% lifetime risk of developing 
active TB. Third, the remaining 5–10% of individuals progress 
directly to active TB and become contagious (184). In this 
context, the mouse model fails to replicate the natural progres-
sion of infection in humans. Although several groups are now 
using very low dose aerosol infections, the majority of studies 
still deliver 50–100 viable M.tb bacilli into the lung to reproduce 
natural infection in humans. In most mouse laboratory strains, 
M.tb replicates in the lung until Ag-specific T cells develop. At 
approximately 3 weeks post-infection, T cells enter the lung and 
stunt M.tb growth (185). M.tb bacterial burden peaks at approxi-
mately one million bacteria (6 log10) in standard mouse strains 
and remains at this level for an extended period of time before 
increasing at the end of life (186).
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Outcome of BCG vaccination in mice and humans is also quite 
distinct. BCG-vaccinated mice are able to contain the M.tb infec-
tion sooner than naïve mice. Where it requires 3 weeks for mice 
to establish stable M.tb CFU, BCG vaccination shifts this pattern 
from 3 to 2 weeks. This allows the mouse to contain the infection 
more rapidly, establishing the bacterial burden at approximately 
100,000 bacteria in the lung (5 log10) (187). This mycobacterial 
“immunity” has been attributed to immunological memory 
(13–15). However, immunity wanes across time. M.tb bacterial 
burden gradually increases back up to one million somewhere 
between 3 and 5 months post-infection. In humans, no studies 
have been conducted to evaluate the direct effects of BCG on the 
control of M.tb at early stages of infection mostly because it is 
extremely challenging to predict when infection will occur in 
a non-controlled setting. Thus, the current data on the efficacy 
of BCG come from clinical trials assessing whether individuals 
developed TB or not. Although it is not the focus of this review 
to discuss human clinical trial data on the effects of BCG vac-
cination, it is important to note that BCG efficacy against PTB 
in humans is predicted to be 60% and wanes with increasing age 
(12, 188).
The best relevant model for vaccine development that faith-
fully recapitulates human TB is the NHP. The two commonly 
used NHP models of TB research are the cynomolgus and rhesus 
macaques (189–191). Most research with BCG, however, has uti-
lized the rhesus model. Rhesus macaques faithfully recapitulate 
human TB. They can develop asymptomatic TB, LTBI, progress 
to active TB, and even reactivate (192–195). The evidence clearly 
indicates that BCG can reduce M.tb bacterial burden in the lung, 
but does not eliminate it (196). Thus, data obtained using animal 
models suggest that BCG may in itself not prevent primary 
infection, but rather may exert its protective effects by containing 
M.tb and preventing progression to disease. Thus, the NHP is the 
ideal to model to screen TB vaccines. However, high costs, ethical 
issues, and challenges of animal handling have left the NHP as 
a last resort model for screening vaccine efficacy, and further, it 
is non-feasible as a high throughput model to test TB vaccine 
candidates.
THe LUNG eNviRONMeNT AND  
BCG vACCiNATiON
Little is known about the role of the lung environment in deter-
mining the quality of immune responses generated during M.tb 
infection and the outcome of active or latent TB disease. The pri-
mary function of the lung is gas exchange and thus, the immune 
response generated within the lung is orchestrated to minimize 
inflammation. There is a delicate balance between generating a 
massive immune response that will be initially detrimental for 
the host and M.tb (i.e., cavities in active TB, destroying lung tissue 
and forcing the bacillus to accelerate replication, and abandon 
the dying host), or an immune response that will favor both (i.e., 
granuloma formation in latent M.tb infection, where both host 
and M.tb live in harmony). The lung environment has an impact 
on this balance. In this regard, the lung mucosa contains an array 
of homeostatic components (hydrolytic enzymes, complement 
proteins, surfactant proteins, antimicrobial enzymes, Igs, and 
many others) whose function is to maintain homeostasis of the 
lung (197, 198). All of these components are associated with the 
lung alveolar lining fluid (ALF) (199, 200). Studies from our 
laboratory have shown that some ALF components (i.e., hydro-
lytic enzymes or hydrolases) are capable of altering the cell wall 
of M.tb with two distinct outcomes, modifications on the M.tb 
cell wall exposing “de novo” motifs on the bacterium cell surface 
and the release of M.tb cell wall fragments to the lung milieu 
(201–204). The interaction of M.tb with human ALF reduces the 
amount of ManLAM and TDM by ~65 and ~40%, respectively, 
from the M.tb cell wall surface (201). It is likely that as M.tb is 
deposited in the alveolar space it will encounter ALF hydrolases 
that will modify its cell wall prior to encountering host cells. 
These M.tb cell wall alterations consequently alter M.tb recogni-
tion by human phagocytes (201–204) with subsequent impact 
on Ag processing and presentation. One question that remains 
is whether these human lung mucosa-induced alterations to the 
M.tb cell wall during its natural path of infection could explain the 
reason why the protective immune response generated by BCG 
vaccination is inadequate against PTB. For example, dominant 
cell wall motifs that drive Ag-specific B and T cell responses to 
intradermal administered BCG may be absent on ALF-exposed 
M.tb in the lung. Alternatively, BCG receptor-mediated uptake 
by epidermal-resident APCs may differ from those of M.tb in the 
lung due to newly exposed motifs on the M.tb cell surface by the 
action of human ALF.
To understand the role of the lung environment in the context 
of BCG vaccination, a valuable approach could be to determine 
how M.tb is modified in the lung prior to encountering alveolar 
compartment cells, how this affects its metabolism, and how it 
differs from the ones that BCG undergoes within the epidermis. 
Indeed, M.tb and BCG cell walls have few biochemical differences 
when grown on agar plates, but their cell wall and metabolism 
may differ as they are exposed to different microenvironments 
during infection (M.tb/lung) or vaccination (BCG/epidermis), 
with potential consequences in establishing effective or non-
effective BCG immunity. Since the lung mucosa may play a 
significant role in how BCG may protect us against TB, the 
direct delivery of BCG into the lungs of humans may prove to be 
superior to the conventional systemic intradermal route of BCG 
administration. Whether it is by modulation of innate immune 
cell activity, activation of T  cells, development of a rapid and 
robust Ab response, or by targeting specific components within 
the bacteria itself, BCG has potential to be further manipulated 
to enhance its efficacy against TB.
CONCLUDiNG ReMARKS
Bacillus Calmette–Guérin remains the only World Health 
Organization supported vaccine we have for the prevention of 
TB, yet lacks the ability to protect against the primary form of TB. 
We have highlighted the current knowledge in the field regard-
ing innate and adaptive immune responses to BCG in the hope 
of stressing the importance of understanding immunological 
mechanisms that give rise to effective mycobacterial immunity. 
The importance of cross talk between the innate and adaptive 
branches of the immune system cannot be overstressed, yet the 
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fundamental question of why BCG fails to fully protect against 
PTB remains. It could be due to coinfections (e.g., helminths, 
EM, etc.) preventing the full development of immune responses 
in the lung, or discrepancies between immune responses at the 
site of vaccine administration vs. the natural route of M.tb infec-
tion through the lungs. Perhaps it is not because BCG is poor at 
generating effective immune responses, but that the immunosup-
pressive status of the lung prevents it from doing so. Similarly, 
BCG could be at its saturation point, and thus further stimula-
tion of the immune system would yield no added immunity. 
The answer could simply lie in shifting research efforts toward a 
more immunogenic route of vaccination. The literature suggests 
that intranasal and/or intratracheal vaccination with BCG is a 
more effective method to develop immunity against M.tb, yet no 
human studies have been published on this matter, mainly due to 
increases in pathology observed in the lungs using this delivery 
method. Thus, finding a way to decrease this inflammation in the 
lungs may open new avenues to explore direct mucosal vaccine 
delivery into the lungs. Efforts directed at exploring immuno-
logical events that occur following intranasal/intratracheal BCG 
vaccination and the status of immune cells within the lung could 
yield valuable answers.
We are now beginning to fully understand that in vitro stud-
ies do not always translate to in vivo. The development of more 
suitable animal models and implementation of −omics research 
could aid in the quest of finding a suitable replacement for BCG. 
Unfortunately, no effective vaccine yet exists for intracellular 
bacterial pathogens. A major question still remains: Is BCG poor 
at stimulating mycobacterial immunity or is M.tb simply adept 
at avoiding immunological responses against it? Furthermore, 
the majority of TB vaccine development research focuses on 
using laboratory strains and thus, does not assess vaccine efficacy 
against M.tb clinical isolates, with different degrees of virulence, 
heavily present in high TB burden regions. Studies directed at 
uncovering the mechanisms behind how BCG successfully 
primes, enhances, accelerates, and maximizes host immune 
recognition of M.tb should be prioritized. Furthermore, we must 
revaluate correlates of protection vs. correlates of risk and their 
implications in vaccine design. The TB field has placed much 
emphasis on the study of IFNγ responses and how they can be 
augmented, yet new evidence suggests that IFNγ is a better cor-
relate of risk than of protection. Thus, we must begin to explore 
the contribution of other immune cells and factors and how they 
can be targeted to develop a more effective vaccine. We must 
also begin to design vaccine clinical trials that ask more refined 
questions about mycobacterial immunity and protection. Until 
we refine our understanding of immunity to mycobacteria, the 
development of a successful TB vaccine will remain a difficult 
task.
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